Sachie Hirai
Overview
Explore the profile of Sachie Hirai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
489
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamaguchi M, Hirai S, Idogawa M, Sumi T, Uchida H, Sakuma Y
Int J Mol Sci
. 2024 Aug;
25(16).
PMID: 39201435
Few effective treatments are available for small cell lung cancer (SCLC), indicating the need to explore new therapeutic options. Here, we focus on an antibody-drug conjugate (ADC) targeting the L1...
2.
Sakuma Y, Hirai S, Yamaguchi M, Idogawa M
Int J Mol Sci
. 2024 Jul;
25(13).
PMID: 39000337
Few efficacious treatment options are available for patients with small cell lung carcinoma (SCLC), indicating the need to develop novel therapeutic approaches. In this study, we explored kinesin family member...
3.
Sakuma Y, Hirai S, Sumi T, Niki T, Yamaguchi M
Biochem Biophys Res Commun
. 2023 Aug;
678:84-89.
PMID: 37619315
EGFR-mutant lung adenocarcinoma (LUAD) mostly depends on EGFR for survival and consequently responds well to EGFR inhibitors. However, resistance to the drugs develops almost universally during treatment. We previously demonstrated...
4.
Yamaguchi M, Hirai S, Idogawa M, Sumi T, Uchida H, Fujitani N, et al.
Exp Cell Res
. 2023 Mar;
426(2):113570.
PMID: 36990421
There are few effective therapies for small cell lung carcinoma (SCLC); thus, we need to develop novel and efficacious treatments. We hypothesized that an antibody-drug conjugate (ADC) could be a...
5.
Hirai S, Idogawa M, Sumi T, Yamaguchi M, Niki T, Sakuma Y
Biochem Biophys Res Commun
. 2022 Sep;
630:24-29.
PMID: 36126466
Non-small cell lung carcinomas (NSCLCs), especially lung adenocarcinomas (LUADs), harbor several driver mutations against which highly effective tyrosine kinase inhibitors (TKIs) are available. Although TKIs are generally effective against certain...
6.
Yamaguchi M, Hirai S, Idogawa M, Uchida H, Sakuma Y
Exp Cell Res
. 2022 Feb;
413(2):113078.
PMID: 35189107
Although MET tyrosine kinase inhibitors (TKIs) are generally effective against non-small cell lung carcinoma (NSCLC) with MET exon 14 skipping mutations (METΔex14), resistance to MET TKIs can occur, indicating the...
7.
Sakuma Y, Hirai S, Sumi T, Tada M, Kojima T, Niki T, et al.
Exp Cell Res
. 2021 Aug;
406(2):112763.
PMID: 34358524
MCL1 is an anti-apoptotic BCL2 family member that is often overexpressed in various malignant tumors. However, few reports have described the role of MCL1 in squamous cell carcinoma (SqCC) derived...
8.
Yamaguchi M, Hirai S, Tanaka Y, Sumi T, Tada M, Takahashi H, et al.
Biochem Biophys Res Commun
. 2020 Jun;
528(2):269-275.
PMID: 32473754
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease that includes fibroblastic foci (FF). It has been increasingly appreciated that the origin of collagen-overproducing cells such as pathological...
9.
Hirai S, Tada M, Yamaguchi M, Niki T, Sakuma Y
Biochem Biophys Res Commun
. 2020 Apr;
526(2):417-423.
PMID: 32223928
Although most EGFR-mutant lung adenocarcinomas initially respond to EGFR inhibitors, disease progression almost inevitably occurs. We previously reported that two EGFR-mutant lung adenocarcinoma cell lines, HCC827 and H1975, contain subpopulations...
10.
Tada M, Sumi T, Tanaka Y, Hirai S, Yamaguchi M, Miyajima M, et al.
Lung Cancer
. 2019 Jun;
133:88-95.
PMID: 31200834
Objectives: MCL1 is an anti-apoptotic BCL2 family member that is highly expressed in various malignant tumors. However, little is known about the role of MCL1 in KRAS-mutant lung adenocarcinomas. In...